Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$76.54 USD
-0.81 (-1.05%)
Updated May 17, 2024 04:00 PM ET
After-Market: $76.57 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXSM 76.54 -0.81(-1.05%)
Will AXSM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for AXSM
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics price target lowered by $3 at Mizuho, here's why
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)